Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib-Reference-Cited by-同舟云学术

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

Published:2021-08-11 Issue:9 Volume:10 Page:1107-1118
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

De Zwart Loeckie¹,Snoeys Jan¹,Jacobs Frank¹,Li Lilian Y.²,Poggesi Italo³,Verboven Peter¹,Goris Ivo¹,Scheers Ellen¹,Wynant Inneke¹,Monshouwer Mario¹,Mamidi Rao N. V. S.⁴

Affiliation:

1. Janssen Research & Development Beerse Belgium

2. Janssen Research & Development Spring House Pennsylvania USA

3. Janssen‐Cilag SpA Cologno Monzese Italy

4. Janssen Research & Development, LLC Raritan New Jersey USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12682

Reference32 articles.

1. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

2. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

3. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

4. BALVERSATM. Prescribing information. Horsham PA: Janssen Products LP; 2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. Accessed December 15 2020.

5. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New drug combination regimen based on pharmacokinetic characteristics—Erdafitinib combined with sertraline or duloxetine;Biomedicine & Pharmacotherapy;2024-10

2. Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy;Xenobiotica;2024-08-28

3. Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations;Clinical Pharmacology in Drug Development;2024-07-24

4. Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants;Clinical Pharmacology in Drug Development;2024-05-13

5. In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692;European Journal of Pharmaceutical Sciences;2024-01